Skip to main content
Premium Trial:

Request an Annual Quote

Arrowhead Releases White Paper on Newly Acquired siRNA Delivery Technology

Premium

Arrowhead Research this week released a white paper detailing the dynamic polyconjugate siRNA-delivery technology it picked up through its recent acquisition of Roche's RNA therapeutics assets.

"Studies in non-human primates have shown that [dynamic polyconjugates, or] DPCs, are highly effective and have safety margins well beyond those currently achievable by other systems,” Arrowhead President and CEO Christopher Anzalone said in a statement. “Moreover, the modular nature of DPC technology and its ability to optimize individual components within the same polymer provide the potential to target all types of cells.”

The white paper can be found here.

The delivery technology was originally developed by Mirus Bio, which Roche acquired in 2008 for $125 million (GSN 7/24/2008).

Despite this and additional investments in RNAi, Roche announced about two years later that it was halting all of its in-house research and development on the gene-silencing technology as part of a broader restructuring effort (GSN 11/18/2010).

Last month, Arrowhead disclosed that it had signed a deal acquiring these assets from Roche in exchange for roughly 10 percent of its stock and million-dollar late-stage milestones (GSN 10/27/2011).

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.